Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib

Chagas disease, caused by the protozoan pathogen Trypanosoma cruzi, remains a challenging infection due to the unavailability of safe and efficacious drugs. Inhibitors of the trypanosome sterol 14α-demethylase enzyme (CYP51), including azole antifungal drugs, are promising candidates for development...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Buckner, Frederick S., Bahia, Maria Terezinha, Suryadevara, Praveen Kumar, White, Karen L., Shackleford, David M., Chennamaneni, Naveen Kumar, Hulverson, Matthew A., Laydbak, Joy U., Chatelain, Eric, Scandale, Ivan, Verlinde, Christophe L. M. J., Charman, Susan A., Lepesheva, Galina I., Gelb, Michael H.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2012
Pynciau:
Experimental Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3421879/
https://ncbi.nlm.nih.gov/pubmed/22777048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.06244-11
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg